Second Investment

RNS Number:6424M
Vision Opportunity China Fund Ltd
28 January 2008


   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES,
              CANADA, AUSTRALIA, REPUBLIC OF SOUTH AFRICA OR JAPAN

28 January 2008

                     Vision Opportunity China Fund Limited

                               Second Investment

Vision Opportunity China Fund Limited ("VOC") (AIM:VOC.L) today announces the
completion of its second investment since listing on the AIM market ("AIM"). VOC
has invested $2,000,000 as part of a $5,000,000 financing for VisCorp Inc.
(OTCBB:VSCO) on substantially the same terms as the $10,225,000 financing
VisCorp completed on January 16, 2008. VisCorp previously announced that on
January 16, 2008 it acquired all of the issued and outstanding capital stock of
Raygere Limited. Raygere conducts its business through Chengdu Tianyin
Pharmaceutical Co., LTD. ("Tianyin"), a corporation organised and existing under
the laws of the People's Republic of China. Tianyin is engaged primarily in the
development, manufacturing, marketing and sale of modernised traditional Chinese
medicines and other pharmaceuticals in China.

Tianyin currently manufactures and markets a comprehensive portfolio of 34
products of which 22 are listed in the National Medicine Catalogue of the
National Medical Insurance programme. Tianyin has a product pipeline of 51
products which are pending regulatory approvals with the China State Food and
Drug Administration.

For the fiscal year 2007 Tianyin achieved revenue and net income of US$20.36m
and US$4.22m respectively.

In return for its investment, VOC received the following:


(a) 10% Convertible Exchangeable Notes in the principal amount of $2,000,000.
The Notes are initially convertible into shares of VisCorp's common stock at
$1.60 per share, and will automatically be exchanged for shares of convertible
preferred stock once VisCorp receives shareholder approval to authorise such
shares. The preferred stock will be convertible into common stock at a
conversion price of $1.60 per share. The closing price of OTCBB: VSCO's common
stock on January 25, 2008 was $2.72.

(b) 5 year warrants to purchase 625,000 shares of VisCorp's common stock at an
exercise price of $2.50 per share.

(c) 7 year warrants to purchase 625,000 shares of VisCorp's common stock at an
exercise price of $3.00 per share.


"We believe the pharmaceutical market in China is an attractive, fast growing
area. Chengdu Tianyin has a comprehensive product portfolio as well as an
extensive sales and marketing team. It has demonstrated a track-record of
profitable growth and we believe the financing will fuel Tianyin's continued
growth" stated Adam Benowitz, the portfolio manager of VOC at Vision Capital
Advisors, LLC.


Enquiries to:

Vision Opportunity China Fund Limited
David Benway, Director / Adam Benowitz, Portfolio Manager
www.vocfund.com                        Tel: [phone]

Fairfax I.S. PLC
Paul Richards/James King               Tel: [phone]

Bankside Consultants Limited
Simon Rothschild/Oliver Winters        Tel: [phone]


NOTE TO EDITORS


Vision Opportunity China Fund Limited

Vision Opportunity China Fund Limited ("VOC") is a closed-ended listed fund
traded on AIM. VOC primarily invests directly in listed companies with
operations principally within Greater China.

Greater China is a collective term for the territories administered by the
People's

Republic of China, those administered by the Republic of China and Singapore.


Chengdu Tianyin Pharmaceutical Co., LTD

Established in 1994, Chengdu Tianyin was a manufacturer and supplier of
modernised traditional Chinese medicines. The current management of Chengdu
Tianyin acquired 100% of the equity interest of Chengdu Tianyin in 2003. Chengdu
Tianyin currently manufactures and markets a comprehensive portfolio of 34
products of which 22 are listed in the National Medicine Catalogue of the
National Medical Insurance programme. Chengdu Tianyin has a product pipeline of
51 products which are pending regulatory approvals with the China State Food and
Drug Administration. The Company has an extensive nationwide distribution
network throughout China with a sales force of over 500 salespeople. Tianyin is
headquartered in Chengdu, Sichuan Province with two manufacturing facilities and
over 1,100 employees. For the fiscal year 2007 Chengdu Tianyin achieved revenue
and net income of US$20.36m and US$4.22m, respectively.



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCVVLBLVFBEBBK